Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron (REGN) Announces Positive Data on Oncology Candidate
10:31am, Friday, 24'th May 2024
Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.
Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically p
Mary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering Fair
12:03pm, Thursday, 23'rd May 2024
DALLAS--(BUSINESS WIRE)--Mary Kay Inc., a corporate cheerleader in support of STEM education and youth pursuing their dreams, recently awarded three grants to five standout high school scientists, sel
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
06:15am, Thursday, 23'rd May 2024
Nvidia achieved some phenomenal returns of late, and even before the emergence of generative artificial intelligence, it was a millionaire maker. Netflix transformed itself from a DVD rental company t
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
04:50pm, Wednesday, 22'nd May 2024
NEW YORK , May 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
02:15pm, Monday, 20'th May 2024
Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent sig
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
01:34pm, Monday, 20'th May 2024
Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have he
International Assets Investment Management LLC Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
04:48am, Monday, 20'th May 2024
International Assets Investment Management LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 13.2% during the fourth quarter, according to its
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world's largest pre-college science, technology, engineering and math (STEM) competition. Grace Su
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
03:54pm, Thursday, 16'th May 2024
NEW YORK--(BUSINESS WIRE)---- $REGN #Investigation--The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Re
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
